Citations |
Acta Biomater. 2022 Aug 1;S1742-7061(22)00455-X.<br>Am J Transl Res. 2019 Sep 15;11(9):6055-6065.<br>Biochem Biophys Res Commun. 2023 Apr 2;650:96-102.<br>Biochem Pharmacol. 2017 Jan 15;124:29-42.<br>Biochim Biophys Acta. 2017 Nov 20;1865(2):354-363.<br>bioRxiv. 2023 Nov 23.<br>bioRxiv. 2023 Sep 18.<br>Br J Cancer. 2021 Jan;124(1):191-206.<br>Br J Cancer. 2022 Jan 14.<br>Cancer Cell. 2017 Apr 10;31(4):576-590.e8. <br>Cancer Res. 2019 Oct 15;79(20):5245-5259.<br>Cancer Res. 2021 Jan 1;81(1):187-198.<br>Cancer Res. 2023 Apr 18;CAN-22-3484.<br>Cancer Res. 2023 Oct 6.<br>Cancers (Basel). 2021, 13(7), 1494.<br>Cancers (Basel). 2023 Mar 22;15(6):1908.<br>Cancers. 2020 Jun 16;12(6):1596.<br>Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.<br>Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. <br>Cell Death Differ. 2020 Jun;27(6):1981-1997.<br>Cell Death Differ. 2022 Jan 20.<br>Cell Death Dis. 2020 Apr 6;11(4):219. <br>Cell Death Dis. 2020 Sep 15;11(9):760.<br>Cell Death Dis. 2022 Apr 2;13(4):295.<br>Cell Mol Gastroenterol Hepatol. 2022 Jul 14;S2352-345X(22)00163-1.<br>Cell Prolif. 2022 Sep 20;e13337.<br>Cell Rep. 2022 Aug 16;40(7):111194.<br>Cell Rep. 2022 Nov 15;111716.<br>Cell Syst. 2018 Apr 25;6(4):424-443.e7.<br>Cell Syst. 2019 Jul 24;9(1):35-48.e5. <br>Cell Rep. 2020 Apr 14;31(2):107514.<br>Cells. 2023 Dec 30, 13(1), 81.<br>Clin Cancer Res. 2021 Apr 1;27(7):1855-1863.<br>Department of Biochemistry. 2020 Oct.<br>Dev Cell. 2023 Sep 9;S1534-5807(23)00443-4.<br>Development. 2023 Apr 5;dev.200903.<br>EBioMedicine. 2019 May;43:171-179. <br>EBioMedicine. 2019 May;43:225-237. <br>EMBO J. 2021 Apr 15;e99692.<br>EMBO Rep. 2022 Apr 11;e53932.<br>Endocrinology. 2023 Sep 13;bqad135.<br>Exp Cell Res. 2020 Aug 1;393(1):112054.<br>Front Cell Dev Biol. 2020 Aug 31;8:843.<br>Front Oncol. 2022 Apr 8;12:819003.<br>Future Med Chem. 2018 Dec 17. <br>Harvard Medical School LINCS LIBRARY<br>Inflamm Res. 2023 May 11.<br>Int J Biol Sci. 2019 Jan 1;15(3):522-532. <br>Int J Biol Sci. 2021; 17(3): 728-741.<br>Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. <br>Int J Mol Sci. 2021, 22(7), 3367.<br>Int J Mol Sci. 2023 Mar 12.<br>iScience. 6 September 2022, 105081.<br>J Biol Chem. 2023 May 3;104786.<br>J Biol Chem. 2023 Oct 17.<br>J Bone Oncol. October 2021, 100391.<br>J Cell Mol Med. 2021 Mar;25(6):3124-3135.<br>J Exp Clin Cancer Res. 2018 Sep 20;37(1):233.<br>J Med Chem. 2021 Jul 21.<br>J Med Chem. 2021 Oct 21.<br>J Oncol. 27 Sept 2022.<br>J Transl Med. 2019 Aug 20;17(1):276.<br>JCI Insight. 2021 Apr 8;6(7):139497.<br>Leuk Res. September 2022, 106920.<br>Life Sciences. 2023 Apr 1, 121652.<br>Mar Drugs. 2020 Sep 27;18(10):494.<br>MedComm. 10 June 2022.<br>Mol Cell. 2017 Oct 19;68(2):336-349.e6.<br>Mol Cell. 2023 Oct 5;83(19):3558-3573.e7.<br>Mol Oncol. 2023 Sep 13.<br>Mol Ther-Nucl Acids. 2023 Mar.<br>Molecules. 2023 May 27, 28(11), 4380.<br>Nat Commun. 2018 Oct 9;9(1):4180. <br>Nat Commun. 2020 Aug 13;11(1):4053.<br>Nat Commun. 2021 Jul 22;12(1):4457.<br>Nat Commun. 2021 Nov 16;12(1):6607.<br>Nat Commun. 2023 Jul 14;14(1):4221.<br>Nat Commun. 2024 Feb 16;15(1):1442.<br>Nat Commun. 2019 Nov 7;10(1):5076. <br>Nat Methods. 2022 Mar;19(3):331-340.<br>Nature Cancer. 2021 Jan;2(1):34-48.<br>Nature. 2017 Aug 24;548(7668):471-475. <br>Nature. 2020 Jul;583(7817):620-624.<br>Neoplasia. 2018 Mar 28;20(5):478-488. <br>NPJ Precis Oncol. 2021 Mar 19;5(1):20.<br>Oncogene. 2022 Jun 9.<br>Patent. US11761044.<br>Patent. US20200108066A1<br>Patent. US20230149350A1.<br>PRACTICAL ONCOLOGY JOURNAL. 2018, 32(3): 193-197.<br>Practical Oncology Journal. 2018,32(03):193-197.<br>Research Square Preprint. 2021 Apr.<br>Research Square Preprint. 2021 Dec.<br>Research Square Preprint. 2023 May 9.<br>Research Square Preprint. 2023 Nov 30.<br>Sci Rep. 2021 Mar 8;11(1):5374.<br>Sci Rep. 2023 Jan 31;13(1):1711.<br>Sci Rep. 2024 May 8;14(1):10582.<br>Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.<br>SSRN. 2022 Nov 21.<br>Technischen Universität Dresden . 11 June 2021.<br>Technischen Universität München. Fakultät für Medizin.<br>University of Coruña. Facultade de Ciencias da Saúde. 2022 Oct.<br>University of Coruña. Facultade de Ciencias. 2022 Jan.<br>University of Dundee. 2023 Jan.<br>University of Texas. UTHealth Graduate School of Biomedical Sciences. 2021 Sep.<br>World J Surg Surgical Res. 2023 Jun 28.<br>Aging Cell. 2022 Mar 9;e13580.<br>bioRxiv. 2023 Mar 30.<br>bioRxiv. 2023 Sep 16.<br>Cancer Res. 2023 Jun 29;CAN-23-0705.<br>Cell Rep. 2019 Mar 5;26(10):2667-2680.e7.<br>EMBO J. 2022 Feb 14;e109760.<br>J Virol. 2023 May 23;e0037023.<br>Laurentian University. Chemical Sciences. 2021 Oct.<br>Mol Cancer. 2022 Aug 30;21(1):171.<br>Nat Commun. 2021 Aug 25;12(1):5112.<br>Nat Commun. 2022 Aug 10;13(1):4689.<br>Nature. 2020 Dec;588(7836):169-173.<br>NPJ Breast Cancer. 2021 Jan 4;7(1):2.<br>Syddansk Universitet. 2023 May 22.<br>bioRxiv. 2023 Mar 15.<br>Cancer Res. 2022 Apr 11;canres.3565.2021.<br>Cell Rep. 2022 Mar 1;38(9):110448.<br>Cell Rep. 2023 Mar 30;42(4):112314.<br>Ecotoxicol Environ Saf. 2020 Dec 1;205:111146.<br>Eur J Cancer. 2018 Oct;102:10-22.<br>J Pathol. 2023 Feb 24.<br>J Transl Med. 2023 Feb 10;21(1):110.<br>Mol Cancer Res. 2018 Mar;16(3):361-377. <br>Mol Cell. 2020 Jun 18;78(6):1096-1113.e8. <br>Mol Cell. 2023 Nov 16;83(22):4062-4077.e5.<br>Mol Oncol. 2017 Aug;11(8):1035-1049.<br>Nature. 2017 Jun 15;546(7658):426-430.<br>University College Dublin. School of Biology and Environmental Science.<br>[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. <br>[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. <br>[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. <br>[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296. |
Product Description |
Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4]. |